Virtus Investment Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

Virtus Investment Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$193K	Buy	62,975 +1,536	+3%	+$5.94K	0.05%	377
2025 Q4	$251K	Buy	61,439 +39,430	+179%	+$195K	0.07%	328
2025 Q3	$107K	Buy	22,009 +3,821	+21%	+$20.1K	0.03%	419
2025 Q2	$92K	Sell	18,188 -5,330	-23%	-$26.2K	0.03%	368
2025 Q1	$124K	Buy	+23,518	New	+$171K	0.03%	386

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtus Investment Advisers's RXRX Position: Q1 2026 in Review

Virtus Investment Advisers increased its Recursion Pharmaceuticals (RXRX) stake by 2.5% in Q1 2026, buying an estimated $5.94K and bringing the position to 62,975 shares worth $193K. The position accounts for 0.05% of the portfolio, ranked #377.

Virtus Investment Advisers first reported a position in RXRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $251K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Virtus Investment Advisers held 62,975 shares of Recursion Pharmaceuticals worth $193K as of Q1 2026.
Virtus Investment Advisers bought 1,536 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.94K.
Recursion Pharmaceuticals made up 0.05% of Virtus Investment Advisers's portfolio in Q1 2026, its #377 holding.
Virtus Investment Advisers first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
Virtus Investment Advisers's Recursion Pharmaceuticals position peaked at $251K in Q4 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.